NLS Pharmaceutics AG (NLSP)

NASDAQ: NLSP · IEX Real-Time Price · USD
0.164
+0.015 (9.77%)
At close: May 17, 2024, 4:00 PM
0.165
+0.001 (0.55%)
After-hours: May 17, 2024, 7:48 PM EDT
9.77%
Market Cap 6.28M
Revenue (ttm) n/a
Net Income (ttm) -12.17M
Shares Out 39.56M
EPS (ttm) -0.32
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 857,963
Open 0.165
Previous Close 0.149
Day's Range 0.153 - 0.177
52-Week Range 0.113 - 1.530
Beta -0.71
Analysts Hold
Price Target n/a
Earnings Date May 28, 2024

About NLSP

NLS Pharmaceutics AG, a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies for patients with rare and complex central nervous system disorders. The company is focusing on the development of treatments for narcolepsy, idiopathic hypersomnia, and other rare sleep disorders, as well as neurodevelopmental disorders, such as attention deficit hyperactivity disorder (ADHD). Its lead product candidates include Quilience to treat excessive daytime sleepiness and cataplexy; and Nolazol for the treatment of AD... [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date Jan 29, 2021
Employees 6
Stock Exchange NASDAQ
Ticker Symbol NLSP
Full Company Profile

Financial Performance

Financial Statements

News

NLS Pharmaceutics Announces Receipt of Staff Delisting Determination from Nasdaq; Intends to Request Hearing

ZÜRICH, SWITZERLAND / ACCESSWIRE / April 19, 2024 / NLS Pharmaceutics Ltd. (NASDAQ:NLSP)(NASDAQ:NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company focused on the discove...

4 weeks ago - Accesswire

NLS Pharmaceutics Announces Closing of $1.75 Million Registered Direct Offering

ZÜRICH, SWITZERLAND / ACCESSWIRE / March 22, 2024 / NLS Pharmaceutics Ltd. (NASDAQ:NLSP)(NASDAQ:NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company focused on the discove...

2 months ago - Accesswire

NLS Pharmaceutics Announces $1.75 Million Registered Direct Offering

ZURICH, SWITZERLAND / ACCESSWIRE / March 20, 2024 / NLS Pharmaceutics Ltd. (Nasdaq:NLSP)(Nasdaq:NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company focused on the discove...

2 months ago - Accesswire

NLS Pharmaceutics Secures Exclusive Global License for Next-Generation Non-Sulfonamide Dual Orexin Agonist Platform

The exclusive License Agreement grants NLS Pharmaceutics global rights to next-generation non-sulfonamide orexin-1 / orexin-2 receptor agonists, tailored to target multiple pathways in neuropharmacolo...

2 months ago - Accesswire

NLS Pharmaceutics to Participate in the BIO-EUROPE Springtime Partnering Event

ZURICH, SWITZERLAND / ACCESSWIRE / March 14, 2024 / NLS Pharmaceutics Ltd. (Nasdaq:NLSP)(Nasdaq:NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company focused on the discove...

2 months ago - Accesswire

Nasdaq Accepts NLS Pharmaceutics' Plan to Regain Listing Compliance

ZURICH, SWITZERLAND / ACCESSWIRE / March 11, 2024 / NLS Pharmaceutics Ltd. (NASDAQ:NLSP)(NASDAQ:NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company focused on the discove...

2 months ago - Accesswire

NLS Pharmaceutics Submits Plan to Regain Listing Compliance With Nasdaq

ZÜRICH, SWITZERLAND / ACCESSWIRE / February 23, 2024 / NLS Pharmaceutics Ltd. (NASDAQ:NLSP)(NASDAQ:NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company focused on the disc...

3 months ago - Accesswire

Notice of Deficiency with Nasdaq Continued Listing Requirements

ZURICH, SWITZERLAND / ACCESSWIRE / January 12, 2024 / NLS Pharmaceutics Ltd. (Nasdaq:NLSP)(Nasdaq:NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company focused on the disco...

4 months ago - Accesswire

NLS Pharmaceutics CEO Issues Letter to Shareholders

ZURICH, SWITZERLAND / ACCESSWIRE / December 29, 2023 / NLS Pharmaceutics Ltd. (Nasdaq:NLSP, NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company, focused on the discovery ...

5 months ago - Accesswire

NLS Pharmaceutics Announces Exclusive Option Agreement to Develop and Commercialize Next Generation Dual Orexin Agonist Platform of Aexon Labs, Inc.

The option agreement grants NLS Pharmaceutics Ltd. the exclusive option to in-license all of Aexon Labs' assets for the potential treatment of narcolepsy and other neuro-degenerative disorders, and al...

6 months ago - Accesswire

NLS Pharmaceutics Announces Election of Additional Board Members

Professor Claudio L. A. Bassetti, MD, is the Chair, Neurology Department, Inselspital, Bern University Hospital and Dean, Medical Faculty, University of Bern, focused on sleep disorders Professor Flor...

6 months ago - Accesswire

NLS Pharmaceutics to Participate in the Oppenheimer Sleep Disorders Summit: Deep Dive into Narcolepsy and Idiopathic Hypersomnia

ZURICH, SWITZERLAND / ACCESSWIRE / November 27, 2023 / NLS Pharmaceutics Ltd. (Nasdaq:NLSP, NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company focused on the discovery a...

6 months ago - Accesswire

NLS Pharmaceutics Announces Selection of Strategic Partner and Securing a Bridge Loan

NLS has executed a non-binding term sheet for licensing of NLS intellectual property NLS has secured an additional bridge loan through insiders to extend cash runway NLS has implemented significant in...

6 months ago - Accesswire

NLS Pharmaceutics Announces Receipt of Nasdaq Minimum Bid Price Notification

ZURICH, SWITZERLAND / ACCESSWIRE / October 25, 2023 / NLS Pharmaceutics Ltd. (Nasdaq:NLSP,NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company focused on the discovery and...

7 months ago - Accesswire

NLS Pharmaceuticals to Reschedule Company Update on Strategic Discussions

ZURICH, SWITZERLAND / ACCESSWIRE / October 19, 2023 / NLS Pharmaceutics Ltd. (Nasdaq:NLSP, NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company focused on the discovery an...

7 months ago - Accesswire

NLS Pharmaceutics Announces Company Update on Strategic Partnerships

Members of Executive Leadership Team to Discuss Company Update on Strategic Discussions and Timeline of Phase 3, NLS to Webcast its Event Friday, October 20 at 11:00am ET ZURICH, SWITZERLAND / ACCESSW...

7 months ago - Accesswire

NLS Pharmaceutics shares rise as narcolepsy treatment moves to phase 3 studies

Shares of NLS Pharmaceutics Ltd. NLSP, +19.57% gained 12% premarket on Monday after the Swiss clinical-stage biopharma company said it would proceed with phase 3 clinical studies of Mazindol ER, a tre...

11 months ago - Market Watch

NLS Pharmaceutics to Proceed with Phase 3 Clinical Program (AMAZE) for Mazindol ER for the Treatment of Narcolepsy Following FDA Review and IRB Approval of the Full Study Protocol

ZÜRICH, SWITZERLAND / ACCESSWIRE / July 3, 2023 / NLS Pharmaceutics Ltd. (Nasdaq:NLSP)(Nasdaq:NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company focused on the discovery...

11 months ago - Accesswire

NLS Pharmaceutics Releases the Results from its Annual General Meeting

ZURICH, SWITZERLAND / ACCESSWIRE / June 30, 2023 / NLS Pharmaceutics Ltd. (Nasdaq:NLSP, NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company focused on the discovery and d...

11 months ago - Accesswire

NLS Pharmaceutics Company Update and Webcast Today Postponed

NLS to Webcast its Event on Thursday, July 6, 2023, at 11:00 am ET ZURICH, SWITERLAND / ACCESSWIRE / June 30, 2023 / NLS Pharmaceutics Ltd. (NASDAQ:NLSP)(NASDAQ:NLSPW) ("NLS" or the "Company"), a Swis...

11 months ago - Accesswire

CORRECTION FROM SOURCE: NLS Pharmaceutics to Participate in the Healthcare Virtual Conference Presented by Maxim Group LLC and Hosted by M-Vest

Presentation to take place on Tuesday, June 20, 2023, at 10:30AM ET ZURICH, SWITZERLAND / ACCESSWIRE / June 19, 2023 / NLS Pharmaceutics Ltd. (Nasdaq: NLSP, NLSPW) ("NLS" or the "Company"), a Swiss cl...

11 months ago - Accesswire

NLS Pharmaceutics Announces Company Update Webcast

Members of Executive Leadership Team to Discuss initiation of Phase 3, Pipeline updates, Key Financials, Corporate Development, and the other topics NLS to Webcast its Event Friday, June 30 at 11:00am...

11 months ago - Accesswire

NLS Pharmaceutics to Participate in the Healthcare Virtual Conference Presented by Maxim Group LLC and Hosted by M-Vest

ZURICH, SWITZERLAND / ACCESSWIRE / June 15, 2023 / NLS Pharmaceutics Ltd. (NASDAQ:NLSP, NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company focused on the discovery and d...

1 year ago - Accesswire

NLS Pharmaceutics Announces Positive Safety Data From In Vitro CYP450 and Transporter Mediated Drug-Drug Interaction Studies of Mazindol

Very low risk for drug-drug interactions (DDI) with Mazindol ER based upon results from in vitro metabolism and transporter studies Demonstrated pharmacological differentiation versus currently availa...

1 year ago - Accesswire

NLS Pharmaceutics Appoints Keith Harrison Dewedoff as Interim Chief Financial Officer

ZÜRICH, SWITZERLAND / ACCESSWIRE / May 8, 2023 / NLS Pharmaceutics Ltd. (NASDAQ:NLSP)(NASDAQ:NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company focused on the discovery ...

1 year ago - Accesswire